Sanofi: new data on RSV to be unveiled at IDWeek

(CercleFinance.com) - Sanofi announces that it will present new data on Beyfortus (nirsevimab) at IDWeek 2024, demonstrating the efficacy and safety of its treatment against respiratory syncytial virus (RSV) in infants.


According to Thomas Triomphe, Executive Vice President of Sanofi Vaccines, Beyfortus demonstrated efficacy of over 80% in its first year of implementation.

Several independent studies, notably in Chile and Spain, will confirm these results during the event, the laboratory assures.


Copyright (c) 2024 CercleFinance.com. All rights reserved.